Investor Presentaiton
Early clinical pipeline features a KRAS and
KRAS enabling program
MRTX1133
Selectively and reversibly binds to and inhibits
KRASG12D in both active and inactive states with
Phase 1
.
•
Additional assets are in preclinical development
⚫ The KRASG12D mutation is implicated in over 30% of
pancreatic cancer patients, a disease with high unmet
medical need
MRTX0902
Potent and selective small molecule SOS1 inhibitor
that disrupts the KRAS SOS1 interaction shifting KRAS
to its inactive state
Potential to be highly synergistic in combination with
KRASG12C, KRASG12D and other targeted agents
⚫ Phase 1/2 combination cohort initiated in Q2 2023 with
initial clinical data expected in 2024
Ill Bristol Myers Squibb™
Not for Product Promotional Use
12View entire presentation